XM không cung cấp dịch vụ cho cư dân của Mỹ.

XM không cung cấp dịch vụ cho cư dân của Mỹ.
S
S

Sanofi

Tin tức

Reuters - 1 ngày trước

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - 1 ngày trước

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - 2 ngày trước

Who in the US benefits from $35 insulin?

EXPLAINER-Who in the US benefits from $35 insulin? By Ahmed Aboulenein WASHINGTON, Oct 30 (Reuters) - Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a major accomplishment of the Biden administration, referring to a provision of the Inflation Reduction Act. Harris, the Democratic presidential candidate, and President Joe Biden describe the cap as one of their most important health policy wins, helping those who often could
S
Reuters - 1 tuần trước

European shares end week in the red as earnings disappoint

UPDATE 2-European shares end week in the red as earnings disappoint Mercedes car earnings plunge as China shuns luxury Electrolux slides on US woes, Chinese competition Signify shares soar as largely in-line Q3 provides relief Updated at 1603 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 25 (Reuters) - Europe's main stock index closed Friday's choppy session flat and notched weekly losses , as a handful of weak corporate earnings from auto-related companies such as Mercedes-Benz a
E
R
S
V
F
Reuters - 1 tuần trước

Sanofi shares seen up after Q3 beat

BUZZ-Sanofi shares seen up after Q3 beat ** Shares in Sanofi SASY.PA are seen up 1%-3.5% after the French pharma giant published Q3 results above expectations ** The group reported net sales for the quarter 6% above consensus at 13.44 billion euros ($14.53 billion), while business net income beat analyst expectations by 15% to 3.59 billion euros ** J.P.
S
Reuters - 1 tuần trước

Sanofi profit growth beats market view on early start of vaccine sales

REFILE-UPDATE 1-Sanofi profit growth beats market view on early start of vaccine sales Refiles with with name of analyst firm in paragraph 7 By Ludwig Burger Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
S
Reuters - 1 tuần trước

MARKETS ENTER THE EVENT STORM

LIVE MARKETS-MARKETS ENTER THE EYE OF RISK-EVENT STORM Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com MARKETS ENTER THE EYE OF RISK-EVENT STORM Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar .
A
A
G
M
S
T
J
U
E
F
U
G
Reuters - 1 tuần trước

Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus

BRIEF-Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus Oct 25 (Reuters) - Sanofi SA SASY.PA : Q3 NET SALES EUR 13,438 MLN VS EUR 12,672 MLN IN VARA CONSENSUS Q3 BUSINESS EPS EUR 2.86 MLN VS EUR 2.49 MLN IN VARA CONSENSUS Q3 FREE CASH FLOW EUR 3,327 MLN, UP 79.5% YOY Q3 GROSS PROFIT EUR 10,074 MLN VS EUR 9,444 MLN IN VARA CONSENSUS
S
Reuters - 1 tuần trước

Sanofi CFO says won't be affected by Novo's Catalent deal

Sanofi CFO says won't be affected by Novo's Catalent deal FRANKFURT, Oct 25 (Reuters) - Sanofi's SASY.PA finance chief on Friday said the company won't be affected by Novo Nordisk's NOVOb.CO controlling shareholder's decision to acquire contract drug manufacturer Catalent CTLT.N , adding the deal made sense for its rival. "They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results .
S
Reuters - 1 tuần trước

Sanofi Q3 earnings beat market view, boosted by vaccine sales

Sanofi Q3 earnings beat market view, boosted by vaccine sales Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines. Quarterly business operating income, excluding one-off items, rose by 14.4% to 4.6 billion euros ($5.0 billion), surpassing the average analyst estimate of 4 billion euros in a poll posted on the company's website.
S
Reuters - 1 tuần trước

Markets enter the eye of risk-event storm

MORNING BID EUROPE-Markets enter the eye of risk-event storm A look at the day ahead in European and global markets from Kevin Buckland Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar . But this relative calm feels like the eye of the storm as risk events swirl on the horizon next week: mega-cap earnings from five of the "Magnificent 7"; a highly
A
A
E
M
S
T
U
J
U
U
U
Reuters - 2 tuần trước

Dealmakers expect bigger European private equity buyouts and more of them

ANALYSIS- Dealmakers expect bigger European private equity buyouts and more of them Number of $5bn plus deals more than doubled in year to date Uninvested cash has piled up Private equity investors press for returns through asset sales By Amy-Jo Crowley, Andres Gonzalez, Mathieu Rosemain and Anousha Sakoui LONDON, Oct 22 (Reuters) - Buyout fund CD&R's keenly awaited 16 billion euro ($17.36 billion) deal to take control of Sanofi's consumer health unit, could herald an upsurge in big private equi
S
Reuters - 2 tuần trước

British Business - Oct. 22

PRESS DIGEST-British Business - Oct. 22 Oct 21 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British engineering company Ricardo RCDO.L said it is divesting its defence business as part of a five-year strategic shift to become an "engineering consultancy in environmental and energy transition".
M
O
P
S
V
V
Reuters - 2 tuần trước

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Secureworks, Atlantic Union Bankshares, Catalent, Viad Corp Updates: EQT AB, DNB, CITIC Ltd Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Cybersecurity firm Sophos, which is backed by private equity firm Thoma Bravo, said it will acquire Secureworks SCWX.O for $859 million in an all-cash deal to strengthen its cybersecurity offering for small, mid and enterprise customers.
M
S
U
D
Reuters - 2 tuần trước

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** China's state-owned CITIC Ltd 0267.HK has agreed to sell its 19.23% stake in Fast Food Holdings, the company behind McDonald's China and Hong Kong operations, to Trustar Fast Food Holdings for $430.3 million.
M
S
U
Reuters - 2 tuần trước

STOXX 600 finishes lower ahead of key earnings reports

UPDATE 2-STOXX 600 finishes lower ahead of key earnings reports For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Forvia jumps on supply deal with China's BYD, Xiaomi SAP, bank earnings in focus this week Updated at 1600 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 21 (Reuters) - European shares ended Monday's choppy session in the red ahead of a series of marquee corporate earnings, although stabilising oil prices buoyed
B
D
L
M
S
S
E
F
I
S
G
Reuters - 2 tuần trước

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 21 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FORVIA FRVIA.PA The company on Monday posted third-quarter sales , flagging some optimism linked to its operation in China. SANOFI SASY.PA The French company said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S.
S
F
N
U
Reuters - 2 tuần trước

Sanofi in exclusive talks with CD&R over sale of $17 bln Opella

UPDATE 3-Sanofi in exclusive talks with CD&R over sale of $17 bln Opella Opella has been valued at around 16 bln euros, Sanofi says Paris given guarantees on jobs and production, sources say Sanofi increases 2024 earnings per share guidance Adds state to take a seat on board in paragraph 2, shares in 9 By Dominique Patton PARIS, Oct 21 (Reuters) - French drugmaker Sanofi SASY.PA said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella t
S
Reuters - 2 tuần trước

Sanofi enters exclusive talks with CD&R for Opella sale

Sanofi enters exclusive talks with CD&R for Opella sale PARIS, Oct 21 (Reuters) - Sanofi SASY.PA said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.38 billion), or 14 times EBITDA in 2024, and French public investment bank Bpifrance is expected to take
S
Reuters - 2 tuần trước

Financial Times - Oct 21

PRESS DIGEST- Financial Times - Oct 21 Oct 21 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Public to be asked for suggestions on how to fix NHS - French state takes stake in Sanofi unit to smooth 15.5 billion euro ($16.84 billion) deal Overview UK health secretary Wes Streeting will on Monday launch a "national conversation" about the future of the National Health Service, which he
S

Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.